Ron Firestein



Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile


A/Prof Ron Firestein, MD PhD - Hudson Institute of Medical Research

Assoc. Prof Firestein is a physician scientist, double board certified in Pathology (Anatomic and Molecular Genetics) specialising in Cancer Research, Oncology Translational Medicine and Oncology Drug Discovery and Biomarker Development.

Dr Firestein earned his BA from the University of Pennsylvania in Biology and his MD/PhD from Stanford University as part of the Medical Scientist Training Program (MSTP) in 2002. He completed residency in Anatomic Pathology at Brigham and Women's Hospital and fellowship in Molecular Pathology at Harvard Medical School, where he received the Thomas Gil award for excellence in research.

Prior to joining the Hudson Institute in August 2015 as head of the Centre for Cancer Research, Assoc. Prof Firestein led a basic research lab and directed clinical translational research spanning from experimental (early discovery) across Phase I/II early clinical biomarker/companion diagnostics development. His basic research focuses on target ID/validation and molecular pathology of colon cancer, using NGS technologies and state of the art functional high throughput screens. His scientific work has resulted in peer reviewed high impact publications (including Nature, Cancer Cell, Cell, and Journal of Clinical Investigation) as well as seven patents.


McCleland M., Blaschke K., Chopra VS., Segal E., Watanabe C., Haley B., Mayba O., Yaylaoglu M., Firestein R. CCAT1 is an enhancer template RNA that predicts BET sensitivity in colorectal cancer. J. Clin. Invest. 2016; 126:639-52.

Storm E., Durinck S., Tremayne J., Klijavin N., Tan C., Ye X., Hongo JA., Firestein R., Blackwood E., Metcalfe C., Yauch B., de Sauvage F. Targeted therapy directed against PTPRK-RSPO3 fusion-positive colorectal tumours inhibit stem cell function and promote differentiation. Nature 2016; 529:97-100.

Junttila M., Mao W., Wang X. Wang B., Pham T., Flygare J., Yu SF., Yee S., Goldenberg D., Fields C., Eastham-Anderson JE., Singh M., Hongo JA., Firestein R., Schutten M., Flagella K., Polakis P., Polson A. Targeting LGR5+ Cells with an Antibody-drug conjugate for the treatment of colon cancer. Sci. Transl. Med. 2015; 7:314

Adler AS., McCleland ML., Yee S., Yaylaoglu M., Hussain S., Cosino E., Quinones G., Modrusan Z., Seshagiri S., Torres E., Chopra VS., Haley B., Zhang Z., Blackwood EM., Singh M., Junttila M., Stephan JP., Liu J., Pau G., Fearon ER., Jiang Z., Firestein R. An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumour growth. Genes Dev 2014; 28:1068-84.

Jaiswal BS., Kljavin NM., Stawiski EW., Chan E., Parikh C., Durinck S., Chaudhuri S., Pujara K., Guillory J., Edgar KA., Janakiraman V., Scholz RP., Bowman KK., Lorenzo M., Li H., Wu J., Yuan W., Peters BA., Kan Z., Stinson J., Mak M., Modrusan Z., Eigenbrot C., Firestein R., Stern HM., Rajalingam K., Schaefer G., Merchant MA., Sliwkowski MX., de Sauvage FJ., Seshagiri S. Oncogenic ERBB3 mutations in human cancer. Cancer Cell 2013; 23:603-17.

Related Links:

  • Director, Centre for Cancer Research, Hudson Institute of Medical Research 

Research area keywords

  • Colon Cancer
  • Colorectal Cancer
  • cancer genetics
  • functional genomics
  • cancer therapeutics
  • bowel malignancies

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

An anti-gdnf family receptor alpha 1 (gfra1 antibody–drug conjugate for the treatment of hormone receptor–positive breast cancer

Bhakta, S., Crocker, L. M., Chen, Y., Hazen, M., Schutten, M. M., Li, D., Kuijl, C., Ohri, R., Zhong, F., Poon, K. A., Go, M. A. T., Cheng, E., Piskol, R., Firestein, R., Fourie-O'Donohue, A., Kozak, K. R., Raab, H., Hongo, J. A., Sampath, D., Dennis, M. S. & 3 others, Scheller, R. H., Polakis, P. & Junutula, J. R., 1 Mar 2018, In : Molecular Cancer Therapeutics. 17, 3, p. 638-649 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
14 Citations (Scopus)

Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State

Daemen, A., Liu, B., Song, K., Kwong, M., Gao, M., Hong, R., Nannini, M., Peterson, D., Liederer, B. M., de la Cruz, C., Sangaraju, D., Jaochico, A., Zhao, X., Sandoval, W., Hunsaker, T., Firestein, R., Latham, S., Sampath, D., Evangelista, M. & Hatzivassiliou, G., 4 Sep 2018, In : Cell Metabolism. 28, 3, p. 383-399 27 p.

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

PLK1 has tumor-suppressive potential in APC-Truncated colon cancer cells

Raab, M., Sanhaji, M., Matthess, Y., Hörlin, A., Lorenz, I., Dötsch, C., Habbe, N., Waidmann, O., Kurunci-Csacsko, E., Firestein, R., Becker, S. & Strebhardt, K., 1 Dec 2018, In : Nature Communications. 9, 1, 17 p., 1106.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
9 Citations (Scopus)

Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative89 Zr-ImmunoPET

van Terwisscha Scheltinga, A. G. T., Ogasawara, A., Pacheco, G., Vanderbilt, A. N., Tinianow, J. N., Gupta, N., Li, D., Firestein, R., Marik, J., Scales, S. J. & Williams, S-P., Jan 2017, In : Molecular Cancer Therapeutics. 16, 1, p. 134-142 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
9 Citations (Scopus)

Targeting the seeds of small cell lung cancer

Mahara, S. & Firestein, R., 1 Mar 2017, In : Annals of Translational Medicine. 5, 5, 113.

Research output: Contribution to journalArticleOtherpeer-review